title: A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions.
abstract: BACKGROUND
  Psoriasis significantly impacts patients' quality of life.
  
  
  OBJECTIVE
  The purpose of this study was to prospectively assess the quality-of-life impact of treatment for moderate to severe plaque psoriasis by using a validated quality-of-life psychometric instrument that has been widely used in nondermatologic settings.
  
  
  METHODS
  In all, 32 patients with moderate to severe plaque psoriasis received 24 weeks of adalimumab treatment. Patients completed the Psychological General Well-Being (PGWB) Index, which evaluates 6 domains including anxiety and depression. The primary end point was the change in total PGWB score at weeks 12 and 24 of adalimumab treatment compared with baseline.
  
  
  RESULTS
  Statistically significant improvement in the total PGWB score was documented by week 4. By week 24, all 6 PGWB domains showed statistically significant improvement from the pretreatment baseline.
  
  
  CONCLUSIONS
  One limitation of this study is that the comparison between our psoriasis data and PGWB data from other major medical conditions was not conducted in a head-to-head manner. Another limitation is that we did not have a controlled (placebo) arm.
  
  
  CONCLUSIONS
  Based on PGWB scores, patients with untreated psoriasis have as much impairment in psychological well-being as patients with other major medical diseases including breast cancer, coronary artery disease, congestive heart failure, and diabetes and that potent intervention improves psychological well-being to where it is comparable with that of patients with asymptomatic hypertension. A prompt intervention with an effective dermatologic treatment is not only critical, but capable of restoring the physical and psychological well-being of patients with psoriasis.
authors.affiliation: Department of Dermatology, University of California, San Francisco, California, USA. tinabhutanimd@gmail.com.
authors.forename: Tina
authors.initials: T
authors.lastname: Bhutani
authors.forename: Tejas
authors.initials: T
authors.lastname: Patel
authors.forename: Bonnie
authors.initials: B
authors.lastname: Koo
authors.forename: Thao
authors.initials: T
authors.lastname: Nguyen
authors.forename: Judith
authors.initials: J
authors.lastname: Hong
authors.forename: John
authors.initials: J
authors.lastname: Koo
mesh_terms: D000068879:Adalimumab; D000222:Adaptation, Physiological; D000223:Adaptation, Psychological; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D011594:Psychometrics; D011788:Quality of Life; D018570:Risk Assessment; D018434:Sickness Impact Profile; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab